share_log

Trinity Biotech | 6-K: Report of foreign private issuer (related to financial reporting)

Trinity Biotech | 6-K: Report of foreign private issuer (related to financial reporting)

Trinity Biotech | 6-K：外國發行人報告（業績相關）
美股SEC公告 ·  2024/08/21 01:58

Moomoo AI 已提取核心訊息

Trinity Biotech reported Q2 2024 revenues of $15.8M, up 14% YoY and 7.7% QoQ, driven by strong TrinScreen HIV performance. Point-of-Care revenue surged 119% YoY to $4.6M, while Clinical Laboratory revenue declined 4.6% to $11.3M. Operating loss improved to $1.7M from $4.0M in Q2 2023.The company is making significant progress on its transformation initiatives, including manufacturing consolidation and corporate services offshoring. Manufacturing transfer of HIV products to offshore partners is completed, while Kansas City plant consolidation remains on track for end-2024. The centralized corporate services site is expected to be operational by Q4 2024.Development of next-generation Continuous Glucose Monitoring system continues as planned, with the first pre-pivotal clinical trial initiated and expected to conclude in September. A second pre-pivotal trial is approved to begin in Q4 2024. The company reiterates guidance to achieve approximately $20M annualized run-rate EBITDASO on $75M annualized revenues by Q2 2025.
Trinity Biotech reported Q2 2024 revenues of $15.8M, up 14% YoY and 7.7% QoQ, driven by strong TrinScreen HIV performance. Point-of-Care revenue surged 119% YoY to $4.6M, while Clinical Laboratory revenue declined 4.6% to $11.3M. Operating loss improved to $1.7M from $4.0M in Q2 2023.The company is making significant progress on its transformation initiatives, including manufacturing consolidation and corporate services offshoring. Manufacturing transfer of HIV products to offshore partners is completed, while Kansas City plant consolidation remains on track for end-2024. The centralized corporate services site is expected to be operational by Q4 2024.Development of next-generation Continuous Glucose Monitoring system continues as planned, with the first pre-pivotal clinical trial initiated and expected to conclude in September. A second pre-pivotal trial is approved to begin in Q4 2024. The company reiterates guidance to achieve approximately $20M annualized run-rate EBITDASO on $75M annualized revenues by Q2 2025.
Trinity Biotech報告稱2024年第二季度營業收入爲1580萬美金，同比增長14%，環比增長7.7%，這主要得益於TrinScreen HIV的強勁表現。即時檢測營業收入同比激增119%，達到460萬美金，而臨牀實驗室營業收入則下降4.6%，降至1130萬美金。運營虧損從2023年第二季度的400萬美金改善至170萬美金。公司在轉型項目上取得了顯著進展，包括製造業整合和企業服務外包。HIV產品轉移至海外合作伙伴的製造業轉移已完成，而堪薩斯城工廠整合仍按計劃在2024年底之前完成。集中化的企業服務中心預計將在2024年第四季度投入運營。下一代連續血糖監測系統的開發按照計劃進行，首個預關鍵臨牀試驗已啓動，預計將在9月結束。第二個預關鍵試驗已獲批准將在2024年第四季度開始。公司重申指南，預計到2025年第二季度實現約2000萬美金的年化運行EBITDASO，營業收入爲7500萬美金。
Trinity Biotech報告稱2024年第二季度營業收入爲1580萬美金，同比增長14%，環比增長7.7%，這主要得益於TrinScreen HIV的強勁表現。即時檢測營業收入同比激增119%，達到460萬美金，而臨牀實驗室營業收入則下降4.6%，降至1130萬美金。運營虧損從2023年第二季度的400萬美金改善至170萬美金。公司在轉型項目上取得了顯著進展，包括製造業整合和企業服務外包。HIV產品轉移至海外合作伙伴的製造業轉移已完成，而堪薩斯城工廠整合仍按計劃在2024年底之前完成。集中化的企業服務中心預計將在2024年第四季度投入運營。下一代連續血糖監測系統的開發按照計劃進行，首個預關鍵臨牀試驗已啓動，預計將在9月結束。第二個預關鍵試驗已獲批准將在2024年第四季度開始。公司重申指南，預計到2025年第二季度實現約2000萬美金的年化運行EBITDASO，營業收入爲7500萬美金。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    相關股票 相關股票
    代碼 迷你走勢 最新價
    沃氪醫療
    WOK
    -- 0.570
    908 Devices
    MASS
    -- 4.480
    Vicarious Surgical
    RBOT
    -- 6.560
    Icecure Medical
    ICCM
    -- 1.176
    Apyx Medical
    APYX
    -- 1.370
    解鎖完整榜單
    重估中國資產
    繼中國開創性的DeepSeek技術推出之後，華爾街大行重估對中國市場的投資前景。
    熱門討論
    中概股財報季火熱：驚喜盈利能否延續漲勢？
    1. 哪些行業可能成為本輪財報季的市場焦點？ 2. 在政府強調科技創新和可持續發展的背景下，你認為哪些行業具有最大的增長潜力？ 展开
    中國兩會：會議前後股票價格變動的關鍵要點